Clinical Trial Update: Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and pharmacodynamics study of RPC1063 in relapsing multiple sclerosis to characterize absorption, exposure, and pharmacodynamic effects…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• RPC1063 (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED